Cancer chronotherapy: Principles, applications, and perspectives

被引:184
作者
Mormont, MC
Levi, F
机构
[1] Hop Paul Brousse, INSERM, F-94800 Villejuif, France
[2] Hop Paul Brousse, Serv Cancerol, F-94800 Villejuif, France
关键词
circadian rhythms; chronopharmacology; chronotherapy; colorectal carcinoma; quality of life; survival;
D O I
10.1002/cncr.11040
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Cell physiology is regulated along the 24-hour timescale by a circathan clock, which is comprised of interconnected molecular loops involving at least nine genes. The cellular clocks are coordinated by the suprachiasmatic nucleus, a hypothalamic pacemaker that also helps the organism adjust to environmental cycles. The rest-activity rhythm is a reliable marker of the circadian system function in both rodents and humans. This circadian organization is responsible for predictable changes in the tolerability and efficacy of anticancer agents, and possibly also may be involved in tumor promotion or growth. METHODS. Expected least toxic times of chemotherapy were extrapolated from experimental models to human subjects with reference to the rest-activity cycle. The clinical relevance of the chronotherapy principle (i.e., treatment administration as a function of rhythms) has been investigated previously in randomized multicenter trials. RESULTS. in the current study, chronotherapeutic schedules were used to safely document activity of the combination of oxaliplatin, 5-fluorouracil, and leucovorin against metastatic colorectal carcinoma and to establish new medicosurgical management for this disease, and were reported to result in unprecedented long-term survival. CONCLUSIONS. Chronotherapy concepts appear to offer further potential to improve current cancer treatment options as well as to optimize the development of new anticancer or supportive agents.
引用
收藏
页码:155 / 169
页数:15
相关论文
共 99 条
[31]  
GAUTHERIE M, 1974, CHRONOBIOLOGIA, V4, P1
[32]   Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer [J].
Giacchetti, S ;
Perpoint, B ;
Zidani, R ;
Le Bail, N ;
Faggiuolo, R ;
Focan, C ;
Chollet, P ;
Llory, JF ;
Letourneau, Y ;
Coudert, B ;
Bertheaut-Cvitkovic, F ;
Larregain-Fournier, D ;
Le Rol, A ;
Walter, S ;
Adam, R ;
Misset, JL ;
Lévi, F .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :136-147
[33]   Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery [J].
Giacchetti, S ;
Itzhaki, M ;
Gruia, G ;
Adam, R ;
Zidani, R ;
Kunstlinger, F ;
Brienza, S ;
Alafaci, E ;
Bertheault-Cvitkovic, F ;
Jasmin, C ;
Reynes, M ;
Bismuth, H ;
Misset, JL ;
Lévi, F .
ANNALS OF ONCOLOGY, 1999, 10 (06) :663-669
[34]  
GIACCHETTI S, 2002, J CLIN ONCOL, V6, P885
[35]   Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma [J].
Granda, TG ;
D'Attino, RM ;
Filipski, E ;
Vrignaud, P ;
Garufi, C ;
Terzoli, E ;
Bissery, MC ;
Lévi, F .
BRITISH JOURNAL OF CANCER, 2002, 86 (06) :999-1005
[36]   Tumor-based rhythms of anticancer efficacy in experimental models [J].
Granda, TG ;
Lévi, F .
CHRONOBIOLOGY INTERNATIONAL, 2002, 19 (01) :21-41
[37]  
HARRIS BE, 1990, CANCER RES, V50, P197
[38]   VARIATION OF GROWTH-RATE OF A RAT-TUMOR DURING A LIGHT-DARK CYCLE - CORRELATION WITH CIRCADIAN FLUCTUATIONS IN TUMOR BLOOD-FLOW [J].
HORI, K ;
ZHANG, QH ;
LI, HC ;
SAITO, S .
BRITISH JOURNAL OF CANCER, 1995, 71 (06) :1163-1168
[39]   CIRCADIAN-SHAPED INFUSIONS OF FLOXURIDINE FOR PROGRESSIVE METASTATIC RENAL-CELL CARCINOMA [J].
HRUSHESKY, WJM ;
VONROEMELING, R ;
LANNING, RM ;
RABATIN, JT .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (09) :1504-1513
[40]   CIRCADIAN TIMING OF CANCER-CHEMOTHERAPY [J].
HRUSHESKY, WJM .
SCIENCE, 1985, 228 (4695) :73-75